(NasdaqGM:FGNX),(NasdaqGM:FGNXP), Certificate of Amendment Changes Name to FG Nexus Inc.,Increases Authorized Shares, Triggers Conversion of Automatic Exercise Pre-Funded Warrants to Common Stock and Expands Outstanding Share Count to Over 35 million Charlotte, NC, Sept. 05, 2025 (GLOBE NEWSWIRE) — Fundamental Global Inc. (Nasdaq: FGNX, FGNXP) (the “Company” or “FG Nexus”), announced that its Certificate of […]

(NASDAQ:ARTL), SOLANA BEACH, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced the closing of its previously announced underwritten public offering of 640,924 shares of its common stock

(NasdaqGM:RAPP), BOSTON and SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) — Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that it will host a conference call and live webcast at

(NYSE:COHR), SAXONBURG, Pa., Sept. 05, 2025 (GLOBE NEWSWIRE) — Coherent Corp. (NYSE: COHR), a global leader in photonics, announced today its membership in the Diode Technology Working Group within the STARFIRE Hub, a collaborative initiative led by Lawrence Livermore National Laboratory (LLNL) to accelerate the development of inertial fusion energy (IFE). This collaboration reflects Coherent's

(NasdaqGM:ETNB), SAN FRANCISCO, Sept. 05, 2025 (GLOBE NEWSWIRE) — 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified

(NasdaqGM:VERA), BRISBANE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 4, 2025, the Compensation Committee of Vera's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 85,000 shares of Class A common stock and restricted stock units (RSUs) underlying 45,250 shares of

(NASDAQ:RVYL), – Genevieve Baer and Ezra Laniado resign from the Board of Directors – SAN DIEGO, CA, Sept. 05, 2025 (GLOBE NEWSWIRE) — RYVYL Inc. (NASDAQ: RVYL) (“RYVYL” or the “Company”) has appointed current CFO George Oliva and Gene Jones to its Board of Directors. Independent directors Genevieve Baer and Ezra Laniado have resigned from

(NASDAQ:ORIC), SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on September 2, 2025 (the “Grant Date”), ORIC granted a total of 292,500 non-qualified stock options and 79,000 restricted

WALTHAM, Mass., Sept. 05, 2025 (GLOBE NEWSWIRE) — Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization and rational therapeutic combinations to target improved efficacy and convenience in the treatment of IBD and other immune-mediated diseases, today announced that Spyre's independent Compensation Committee of the

The Law Offices of Frank R. Cruz announces that investors with losses related to Sable Offshore Corp. (“Sable” or the “Company”) (NYSE:SOC) have opportunity to lead the securities fraud class action lawsuit. https://mma.prnewswire.com/media/1221557/The_Law_Offices_of_Frank_R_Cruz_Logo.jpg IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN SABLE OFFSHORE CORP. (SOC), CLICK HERE BEFORE SEPTEMBER 26, 2025 (THE LEAD